Catalog No.
DHB95901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
T-cell surface antigen T4/Leu-3, T-cell surface glycoprotein CD4, CD4
Concentration
1.91 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01730
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Hu5A8, TMB-355, TNX-355, CAS: 680188-33-4
Clone ID
Ibalizumab
Ibalizumab, PMID: 29746266
Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection, PMID: 31970712
Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection, PMID: 30885900
Ibalizumab: First Global Approval, PMID: 29675744
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1, PMID: 30110589
Ibalizumab, PMID: 31643628
Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection, PMID: 32659101
Ibalizumab, PMID: 30000027
Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients, PMID: 30378502
Ibalizumab for the treatment of multidrug-resistant HIV-1 infection, PMID: 30740610
Ibalizumab-uiyk (Trogarzo) for multidrug-resistant HIV, PMID: 29667947
Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy, PMID: 29230203
Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty, PMID: 30110580
Cancer immunotherapy via targeted TGF-β signalling blockade in T H cells, PMID: 33087933
Bictegravir/emtricitabine/tenofovir alafenamide, Ibalizumab, and Ozenoxacin, PMID: 29954693
Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States, PMID: 31929403
Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection, PMID: 17668367
Correction to: Ibalizumab: First Global Approval, PMID: 29846911
Antibodies to watch in 2019, PMID: 30516432
Ibalizumab-human CD4 receptor interaction: computational alanine scanning molecular dynamics studies, PMID: 25756667
Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study, PMID: 33427765
Insight into the modified Ibalizumab-human CD4 receptor interactions: using a computational binding free energy approach, PMID: 25342515
Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients, PMID: 20463063
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance, PMID: 33105172
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope, PMID: 23023102
Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab, PMID: 21289125
Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection, PMID: 20639524
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults, PMID: 19015347
Antibody-based strategies in HIV therapy, PMID: 33045349
Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report, PMID: 34111306
The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States, PMID: 33532919
Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity, PMID: 24097413
Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies, PMID: 27792681
Anti-HIV-1 Antibodies: An Update, PMID: 32152957
Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody, PMID: 21134642
Pharmaceutical Approval Update, PMID: 29896030
Next-generation oral preexposure prophylaxis: beyond tenofovir, PMID: 23032733
Choosing appropriate pharmacotherapy for drug-resistant HIV, PMID: 30676115
The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment, PMID: 22001594
HIV-1 entry inhibitors: recent development and clinical use, PMID: 23290628
New Drugs 2019, part 2, PMID: 31022027
Generative models of conformational dynamics, PMID: 24446358
Recent advances in antiretroviral drugs, PMID: 20698725
HIV-1 entry inhibitors: an overview, PMID: 19339945
Antibodies to watch in 2018, PMID: 29300693
New drug for multidrug-resistant HIV, PMID: 29621221
Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans, PMID: 33073698
An option for treatment of multidrug-resistant HIV, PMID: 30194407
Current Status of the Pharmacokinetics and Pharmacodynamics of HIV-1 Entry Inhibitors and HIV Therapy, PMID: 28738768
Monoclonal Antibodies Against Infectious Microbes: So Long and Too Little!, PMID: 32164518
For research use only. Not for human or drug use.
